|
Status |
Public on Jun 06, 2022 |
Title |
Chemotherapy response in cholangiocarcinoma |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
CCLP cholangiocarcinoma cells were transfected with CTRL inhibitor or MIR1249 inhibitor for 48 hours and treated with DMSO or chemotherapy (cisplatin and gemcitabine) for 48 hours before being collected and analysed for gene expression
|
|
|
Overall design |
Dual channel microarrays where Cy3 is Experimental sample RNA and Cy5 is Agilent human reference RNA (cat no 740000).
|
|
|
Contributor(s) |
Braconi C |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
Submission date |
Jun 06, 2019 |
Last update date |
Jun 07, 2022 |
Contact name |
Chiara Braconi |
E-mail(s) |
chiarabraconi@gmail.com
|
Organization name |
University of Glasgow
|
Department |
Wolfson Wohl Cancer Research Centre
|
Street address |
Switchback road
|
City |
Glasgow |
ZIP/Postal code |
G61 1QH |
Country |
United Kingdom |
|
|
Platforms (1) |
GPL21185 |
Agilent-072363 SurePrint G3 Human GE v3 8x60K Microarray 039494 [Probe Name Version] |
|
Samples (9)
|
GSM3856483 |
Cells transfected with MIR-inihbitor control and treated with DMSO_1 |
GSM3856484 |
Cells transfected with MIR-inihbitor control and treated with DMSO_2 |
GSM3856485 |
Cells transfected with MIR-inihbitor control and treated with DMSO_3 |
GSM3856486 |
Cells transfected with MIR-inihbitor control and treated with cisplatin and gemcitabine_4 |
GSM3856487 |
Cells transfected with MIR-inihbitor control and treated with cisplatin and gemcitabine_5 |
GSM3856488 |
Cells transfected with MIR-inihbitor control and treated with cisplatin and gemcitabine_6 |
GSM3856489 |
Cells transfected with MIR-1249 inhibitor and treated with cisplatin and gemcitabine_7 |
GSM3856490 |
Cells transfected with MIR-1249 inhibitor and treated with cisplatin and gemcitabine_8 |
GSM3856491 |
Cells transfected with MIR-1249 inhibitor and treated with cisplatin and gemcitabine_9 |
|
Relations |
BioProject |
PRJNA547616 |